Investigational Drug Information for Otamixaban
What is the drug development status for Otamixaban?
Otamixaban is an investigational drug.
There have been 5 clinical trials for Otamixaban.
The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2010.
The most common disease conditions in clinical trials are Acute Coronary Syndrome, Infarction, and Angina, Unstable. The leading clinical trial sponsors are Sanofi and [disabled in preview].
Summary for Otamixaban
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,200 |
| WIPO Patent Applications | 395 |
| Japanese Patent Applications | 230 |
| Clinical Trial Progress | Phase 3 (2010-04-01) |
| Vendors | 33 |
Recent Clinical Trials for Otamixaban
| Title | Sponsor | Phase |
|---|---|---|
| Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild and Moderate Hepatic Impairment | Sanofi | Phase 1 |
| Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy | Sanofi | Phase 3 |
| Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild, Moderate and Severe Renal Impairment | Sanofi | Phase 1 |
Clinical Trial Summary for Otamixaban
Top disease conditions for Otamixaban
Top clinical trial sponsors for Otamixaban
US Patents for Otamixaban
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
Otamixaban Development Update, Patent Status, and Market Projection
Otamixaban is a discontinued investigational intravenous direct factor Xa inhibitor developed by Sanofi for acute coronary syndromes. Its Phase III SEPIA-ACS2 trial failed to reduce ischemic events compared with unfractionated heparin plus eptifibatide and caused substantially more bleeding. Sanofi discontinued development in 2011. Otamixaban has no FDA approval, no Orange Book listing, no marketed product, and no credible near-term commercial market projection. [1-4]
What is the current development status of otamixaban?
Otamixaban development is inactive. Sanofi stopped the program after the Phase III SEPIA-ACS2 TIMI 52 trial failed its primary efficacy endpoint. The candidate has not advanced into a new indication, formulation, or regulatory pathway since that decision. [1,2]
| Development element | Status |
|---|---|
| Active ingredient | Otamixaban, an intravenous direct factor Xa inhibitor |
| Developer | Sanofi |
| Primary indication | Non-ST-elevation acute coronary syndromes |
| Administration | Intravenous bolus and infusion |
| Development stage reached | Phase III |
| Regulatory approval | None |
| FDA approval date | None |
| Commercial launch | None |
| Current clinical development | Discontinued |
| Current revenue | Zero product revenue |
Otamixaban was designed to provide rapid, direct inhibition of factor Xa during acute coronary intervention and related hospital treatment. The development strategy focused on replacing or improving upon unfractionated heparin and other parenteral anticoagulants used with antiplatelet therapy.
Why did Sanofi discontinue otamixaban?
The Phase III SEPIA-ACS2 trial did not show a meaningful efficacy advantage and showed a clinically unfavorable bleeding profile. The trial enrolled more than 15,000 patients with non-ST-elevation acute coronary syndromes.
| Outcome in SEPIA-ACS2 | Otamixaban | Control therapy | Result |
|---|---|---|---|
| Primary ischemic endpoint | 5.5% | 5.7% | No significant benefit |
| TIMI major or minor bleeding | Approximately 3.1% | Approximately 1.5% | About twofold higher with otamixaban |
| Trial conclusion | No efficacy improvement | Standard comparator | Development did not support continuation |
The trial compared otamixaban with unfractionated heparin plus eptifibatide. Otamixaban failed to improve the composite ischemic endpoint of death, myocardial infarction, recurrent ischemia requiring urgent revascularization, or stent thrombosis. Bleeding was materially higher with otamixaban. [2]
Sanofi announced termination of the program in July 2011 after reviewing the SEPIA-ACS2 results. The company did not pursue a reformulated dose, a narrower patient population, or a secondary indication. [1]
What were the key otamixaban clinical trials?
SEPIA-ACS1 TIMI 42
SEPIA-ACS1 was a Phase II dose-finding study in patients with non-ST-elevation acute coronary syndromes. It evaluated several otamixaban dosing regimens against unfractionated heparin plus eptifibatide.
The study indicated that otamixaban could reduce ischemic events at selected doses, but higher exposure increased bleeding. The dose-response relationship created a narrow therapeutic margin for the subsequent Phase III program.
SEPIA-ACS2 TIMI 52
SEPIA-ACS2 was the pivotal Phase III study. It evaluated otamixaban in a large acute coronary syndrome population undergoing an invasive or conservative treatment strategy.
The trial did not confirm the Phase II efficacy signal. Bleeding risk increased without a corresponding reduction in ischemic events. The clinical profile was unfavorable against established parenteral anticoagulants, and Sanofi terminated the program.
| Trial | Phase | Population | Comparator | Outcome |
|---|---|---|---|---|
| SEPIA-ACS1 TIMI 42 | II | Non-ST-elevation ACS | UFH plus eptifibatide | Dose-response signal, bleeding concerns |
| SEPIA-ACS2 TIMI 52 | III | More than 15,000 NSTE-ACS patients | UFH plus eptifibatide | No efficacy benefit, higher bleeding |
| Post-Phase III program | Not applicable | No new clinical population | Not applicable | Discontinued |
What is the FDA regulatory status of otamixaban?
Otamixaban is not FDA approved. There is no approved otamixaban product in Drugs@FDA, no approved labeling, and no recognized U.S. marketing authorization. [3]
The candidate also has no established FDA exclusivity period. It did not receive new chemical entity exclusivity, orphan-drug exclusivity, pediatric exclusivity, or approval-related market exclusivity because no application produced an approved product.
What is the Orange Book status of otamixaban?
Otamixaban has no Orange Book listing. The FDA Orange Book lists approved drug products and relevant patents or exclusivity associated with approved applications. Because otamixaban was never approved, there is no listed reference product, no Orange Book patent certification pathway, and no standard Paragraph IV challenge against an otamixaban product. [4]
What patents protect otamixaban?
Otamixaban was developed as a proprietary Sanofi compound, but there is no active FDA-listed patent estate associated with a marketed otamixaban product.
The key commercial distinction is that a patent may have existed at the compound, formulation, or manufacturing level without creating an active Orange Book barrier. Since otamixaban never received FDA approval, there is no approved-product patent listing to block a generic filing.
| Patent category | Commercial status |
|---|---|
| Compound patent | Historical development protection may have existed |
| Formulation patent | No approved U.S. product listing |
| Method-of-use patent | No FDA-approved use tied to otamixaban |
| Manufacturing patent | Could affect production, but no marketed product is known |
| Orange Book patent | None |
| Paragraph IV litigation | None identified against an approved otamixaban reference product |
The absence of an Orange Book listing does not mean every historical patent family has expired or been abandoned. It means those patents do not create a current FDA-listed barrier comparable to the patent estate for an approved branded drug.
When does otamixaban lose exclusivity?
Otamixaban has no current FDA market exclusivity because it never obtained approval. The practical exclusivity event was the failure and discontinuation of clinical development, not a defined patent-expiration date.
No generic company has a commercial incentive to file an abbreviated new drug application for otamixaban without an approved reference product and an established clinical market. A new sponsor would likely need to pursue a full development and approval strategy rather than rely on a conventional ANDA pathway.
Are there Paragraph IV challenges or otamixaban patent lawsuits?
No commercially significant Paragraph IV litigation is associated with otamixaban. The reason is structural: there is no approved otamixaban reference listed in the Orange Book.
No major U.S. patent litigation, settlement agreement, or generic launch dispute has shaped the product's commercial status. Sanofi's decision ended the program before a branded launch created the usual patent, licensing, or generic-entry disputes.
Are there formulation patents or manufacturing barriers?
Otamixaban was administered intravenously, which created technical requirements involving sterility, stability, dosing precision, and hospital-use preparation. Those requirements could have supported formulation or manufacturing patent claims during development.
They do not create a significant current market barrier because:
- There is no approved commercial formulation.
- No active branded supply chain exists.
- No established hospital purchasing market exists.
- A new sponsor would need to reproduce the clinical benefit and establish an acceptable bleeding profile.
- The principal barrier is clinical validation, not formulation access.
A follow-on developer could theoretically investigate a lower-dose regimen, a targeted procedural indication, or a redesigned delivery system. The Phase III failure makes that strategy commercially difficult because the core risk was an unfavorable benefit-risk balance rather than a simple delivery limitation.
How does otamixaban compare with competing anticoagulants?
Otamixaban competed in a hospital anticoagulation market dominated by established therapies and newer agents with stronger clinical positioning.
| Drug or class | Primary role in the relevant market | Commercial position versus otamixaban |
|---|---|---|
| Unfractionated heparin | Procedural and acute hospital anticoagulation | Established standard and comparator |
| Bivalirudin | Direct thrombin inhibitor for procedural anticoagulation | Approved and commercially established |
| Fondaparinux | Factor Xa pathway anticoagulation in ACS | Approved for selected ACS use |
| Eptifibatide | GP IIb/IIIa antiplatelet therapy | Used with anticoagulants in the pivotal trial |
| Rivaroxaban | Oral factor Xa inhibitor | Approved for selected cardiovascular indications, not a direct otamixaban substitute in the Phase III setting |
| Apixaban | Oral factor Xa inhibitor | Stronger commercial franchise in chronic indications |
| Otamixaban | Intravenous investigational factor Xa inhibitor | Discontinued and unapproved |
Otamixaban's mechanism was differentiated from heparin, but mechanistic differentiation did not translate into superior clinical outcomes. The program also faced competition from agents with established dosing protocols, hospital familiarity, and regulatory approval.
What is the market projection for otamixaban?
The base-case market projection is zero. Otamixaban has no approved indication, no active commercial supply, no sales, and no identifiable near-term launch pathway.
| Projection scenario | Probability assessment | Commercial implication |
|---|---|---|
| No further development | Base case | No revenue and no market share |
| Restart by Sanofi | Highly remote | Would require a new clinical and regulatory program |
| Licensing to another company | Remote | Limited value after Phase III failure |
| Reformulation or lower-dose development | Speculative | Requires new proof of efficacy and bleeding control |
| Generic or biosimilar entry | Not applicable | Otamixaban is a small molecule, not a biologic, and has no approved reference product |
A relaunch would require more than manufacturing access. A sponsor would likely need to:
- Define a patient population with a clearer benefit-risk profile.
- Select a dose that avoids excess bleeding.
- Conduct a new pivotal trial.
- Establish compatibility with contemporary antiplatelet and interventional treatment.
- Obtain FDA approval for a new drug application.
- Build hospital adoption against low-cost heparin and established alternatives.
The commercial opportunity is therefore limited by development risk, not by patent expiry. A successful relaunch would also face generic pricing pressure from heparin and intense competition from approved anticoagulants.
Which companies are challenging otamixaban?
No major company is publicly pursuing a commercial challenge to otamixaban. The candidate is not an active branded product, and there is no identified generic, biosimilar, or competing licensee preparing a launch.
Biosimilar competition is irrelevant because otamixaban is a chemically synthesized small molecule rather than a biologic. A future copy product would be evaluated under a small-molecule drug pathway, but the absence of an approved reference product makes a standard generic strategy impractical.
What licensing deals involve otamixaban?
No material current licensing or commercialization agreement has established a market for otamixaban. Sanofi was the principal developer and retained control of the program through its discontinuation.
There is no publicly established post-discontinuation transaction that has revived otamixaban development or transferred the asset into an active clinical portfolio.
What patent strength does otamixaban have today?
Otamixaban has low practical patent strength as a commercial asset. Any historical compound or process patents must be assessed separately from FDA-listed protection, but they do not support an active branded market.
| Patent-strength factor | Assessment |
|---|---|
| Approved product | None |
| Orange Book protection | None |
| Active clinical program | None |
| Generic challenge risk | Low relevance because no product is marketed |
| Manufacturing exclusivity | No demonstrated commercial effect |
| Litigation leverage | Minimal |
| Asset value | Primarily contingent on successful redevelopment |
Key Takeaways
- Otamixaban is a discontinued Sanofi intravenous factor Xa inhibitor.
- Sanofi ended development after the Phase III SEPIA-ACS2 trial showed no ischemic benefit and approximately twice the bleeding rate of control therapy.
- The FDA has never approved otamixaban.
- Otamixaban has no Orange Book listing, FDA exclusivity, marketed formulation, or approved reference product.
- No meaningful Paragraph IV litigation, generic challenge, biosimilar risk, or commercial settlement is associated with the asset.
- The current market projection is zero revenue.
- Any future value would depend on a new development program that solves the failed benefit-risk balance.
FAQs
Could otamixaban be revived for a different indication?
Yes, in principle, but revival would require new clinical evidence and likely a new pivotal trial. The prior Phase III failure would remain a central regulatory and commercial liability.
Is otamixaban a direct oral anticoagulant?
No. Otamixaban was developed as an intravenous direct factor Xa inhibitor for acute hospital use. It was not positioned as an oral chronic anticoagulant like rivaroxaban or apixaban.
Is otamixaban interchangeable with rivaroxaban?
No. Both inhibit factor Xa, but they have different routes of administration, clinical settings, dosing strategies, and regulatory histories.
Does otamixaban have biosimilar competition?
No. Biosimilar rules apply to biologic products. Otamixaban is a small-molecule drug candidate and was never approved as a biologic or reference product.
What caused the commercial failure of otamixaban?
The program failed because the pivotal trial did not improve ischemic outcomes and increased bleeding. The resulting benefit-risk profile did not justify regulatory approval or commercial investment.
References
-
Sanofi. (2011, July 21). Sanofi discontinues development of otamixaban in acute coronary syndromes. Sanofi press release.
-
Steg, P. G., Mehta, S. R., Pollack, C. V., Jr., Huber, K.,Ido, A., Clark, A. M., et al. (2013). Otamixaban for acute coronary syndromes. New England Journal of Medicine, 368(22), 2084-2094. https://doi.org/10.1056/NEJMoa1301541
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
More… ↓
